Treatment of giant cell arteritis with tocilizumab is a hot topic at this year’s ACR meeting and, while GiACTA data was promising, a Swiss study reported less-favorable results at the poster session this morning (

Why do diseases manifest in some family members but not in others? Antibodies can be found in patients who do not meet criteria for treatment, especially in first-degree relatives.

Dr Cush reviews highlights from this week on RheumNow.com

For me and many others, this is the Super Bowl of meetings. I haven’t missed an ACR meeting since I started going as a fellow in 1984. In this span of 30 years I have acquired insights on how to navigate such a big meeting. When I say big, I mean over 14,000 attendees from over 100 countries swarming throughout a convention center that has the elements of the Texas state fair, a gigantic Costco (on Saturday), and a sold-out concert.

The PRECISION study will be presented on Tuesday, November 15, 2016 by Dr. Elaine Husni from the Cleveland Clinic. This report brings to a climax the controversy ignited by the February 2005 3 day FDA Arthritis Advisory Committee review of the safety of the blockbuster COX-2 inhibitors, celecoxib, rofecoxib, and valdecoxib.

At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.

Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.

Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.

CreakyJoints will be presenting 5 Posters at the 2016 ACR/AHRP Annual Meeting. At the meeting they will also announce the publication of first-ever Rheumatoid Arthritis Patient Guidelines. 

Amgen has released the presentation times and locations for 21 abstracts to be presented at the ACR/ARHP 2016 Annual Meeting in Washington next week.

At the upcoming 2016 ACR/ARHP Annual Meeting, Genentech will present 15 oral presentations from 17 abstracts relating to the use of tocilizumab and rituximab in a number of varied autoimmune conditions.

Crescendo Bioscience has announced that it will have 4 poster presentations at the American College of Rheumatology 2016 Annual Meeting next week.

Dr. Jerome Greenberg from UCLA has published 10 tips and pearls (based on years of teaching and experience) on immunizations in an out-patient practice:

Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.

ACP released clinical practice guidelines for the diagnosis and management of gout. Interestingly, these are not always aligned with the 2012 ACR gout guidelines.

The MMWR has reported that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), previously (1999) had an estimated 1.8 million (0.9%) prevalence. But as of 2015, an estimated 3.1 million (1.3%) of U.S.

Dr. Jack Cush reviews highlights, news and journal reports from this week at RheumNow.com

Following is a list of top tweets in September and October 2016; they were selected based on the number of clicks, retweets and likes by the viewership. More than 40,000 people were reached with the first one on our list.

Dr. Cush Reviews Highlights from the past week on RheumNow.com. Register to receive free daily rheumatology news written by rheumatologists for rheumatologists. Download the podcast at iTunes.com.

Dr Jack Cush reviews highlights from the news and journal articles appearing this week on RheumNow.com: